Warmly congratulate Beijing Leadingpharm Medicine Technology Development Co.,Ltd. on being selected as the pilot unit of intellectual property rights in Beijing in 2020-2022

Recently, the EG-017 Phase II clinical trial program seminar and kick-off meeting jointly conducted by Beijing New Leading Zhengzhou Deep Blue Sea and Ningbo Xijian Pharmaceutical Technology Co., Ltd. was successfully held in the form of offline main venue (Beijing)+online video conference.

Recently, the Phase III clinical trial scheme discussion of recombinant human erythropoietin -Fc fusion protein for injection (hereinafter referred to as "rhEPO-Fc fusion protein") jointly conducted by Beijing New Leading Zhengzhou Deep Blue Sea and Shandong Danhong Pharmaceutical (a wholly-owned subsidiary of Buchang Pharmaceutical) was successfully held in the form of offline main venue (Beijing)+online video conference.